HUMA Stock Analysis: Buy, Sell, or Hold?
HUMA - Humacyte, Inc. Common Stock
$0.64
-0.04 (-5.75%)
âŧ
5d:
+6.18%
30d:
+0.56%
90d:
-37.04%
WAIT
LOW Confidence
Analysis Updated: Aug 21, 2026 12:00 AM ET
Earnings: Aug 10, 2026
0d
Get Alerted When HUMA Hits Your Target Price
Join 10,000+ traders who never miss a move
You're in! Check your email to confirm and set your target price.
100% Free
No spam, ever
Unsubscribe anytime
Interactive Price Chart (1 Month)
Loading chart...
Loading historical data...
Bottom Line:
âšī¸ NEUTRAL: HUMA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
âšī¸ NEUTRAL: HUMA is fairly priced but lacks strong directional signals. Wait for clearer setup or better entry on dips.
In-depth Analysis How we analyze
Valuation Analysis: HUMA is currently trading at $0.64, which is considered fair relative to its 30-day fair value range of $0.62 to $0.71.
Technical Outlook: Technically, HUMA is in a strong downtrend. Immediate support is located at $0.53, while resistance sits at $0.75. Short-term momentum is weak, with the stock down 5.8% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $1.85 (+188.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Technical Outlook: Technically, HUMA is in a strong downtrend. Immediate support is located at $0.53, while resistance sits at $0.75. Short-term momentum is weak, with the stock down 5.8% recently.
Market Sentiment: The stock scores a mixed 40/100 on our bottoming-setup gauge, with only partial signs of a stabilized entry point. Wall Street analysts see significant upside, with an average price target of $1.85 (+188.1%). Current signals suggest waiting for a better entry point before initiating new positions.
Quick Decision Summary
Current Position
FAIR
Historical Trading Range
$0.62 -
$0.71
Company Quality Score
47/100
(HOLD)
Volume Confirmation
HIGH
Confidence Score
69.5%
All Signals
- NEUTRAL: Price in fair range
- NEUTRAL: Mixed technical signals (40/100)
- BULLISH: High volume confirmation
- BEARISH: Downward momentum (-5.8%)
- BULLISH: Trading 188.1% below Wall St target ($1.85)
- WARNING: Composite score 47/100 in the bottom quintile â this cohort historically lags the market
Trading Range Analysis
30-Day Trading Range
$0.62 -
$0.71
Current vs Trading Range
FAIR
Support & Resistance Levels
Support Level
$0.53
Resistance Level
$0.75
Current Trend
Strong Downtrend
Technical data as of
Aug 21, 2026
Fundamental Context
Forward P/E (Next Year Est.)
-2.59
Wall Street Target
$1.85
(+188.1%)
Revenue Growth (YoY)
34.9%
Share & Embed Analysis
Last updated: August 24, 2026 1:27 AM ET
Data refreshes hourly during market hours. Next update: 2:27 AM
Data refreshes hourly during market hours. Next update: 2:27 AM
đĨ Top Stocks Breaking Out Now
| Ticker | Score | Recommendation | Change % |
|---|
Technical Signals Check
Is HUMA showing a specific setup today?
Insider Activity (6 Months)
0
Buys
0
Sells
0
Net
NEUTRAL
Top Rated Biotechnology Stocks
Top-rated stocks in Biotechnology by analyst ratings.
| Stock | Analyst Consensus | Analyst Target | Tradestie Score |
|---|---|---|---|
|
DNLI
Denali Therapeutics Inc |
STRONG BUY
19 analysts |
$35 | 50 HOLD |
|
MIRM
Mirum Pharmaceuticals Inc |
STRONG BUY
10 analysts |
$138 | 66 BUY |
|
RNA
Atrium Therapeutics, IncâĻ |
STRONG BUY
15 analysts |
$25 | 37 SELL |
|
IRON
Disc Medicine Inc. |
STRONG BUY
11 analysts |
$102 | 50 HOLD |
|
SMMT
Summit Therapeutics PLC |
STRONG BUY
10 analysts |
$29 | 55 HOLD |
